TRENTAL Drug Patent Profile
✉ Email this page to a colleague
When do Trental patents expire, and when can generic versions of Trental launch?
Trental is a drug marketed by Validus Pharms and is included in one NDA.
The generic ingredient in TRENTAL is pentoxifylline. There are fourteen drug master file entries for this compound. Nine suppliers are listed for this compound. Additional details are available on the pentoxifylline profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Trental
A generic version of TRENTAL was approved as pentoxifylline by RISING on July 8th, 1997.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for TRENTAL?
- What are the global sales for TRENTAL?
- What is Average Wholesale Price for TRENTAL?
Summary for TRENTAL
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 102 |
| Clinical Trials: | 45 |
| Patent Applications: | 4,955 |
| DailyMed Link: | TRENTAL at DailyMed |
Recent Clinical Trials for TRENTAL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Tanta University | Phase 4 |
| Tanta University | Early Phase 1 |
| Misr University for Science and Technology | Phase 2 |
US Patents and Regulatory Information for TRENTAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Validus Pharms | TRENTAL | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 018631-001 | Aug 30, 1984 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for TRENTAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Validus Pharms | TRENTAL | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 018631-001 | Aug 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| Validus Pharms | TRENTAL | pentoxifylline | TABLET, EXTENDED RELEASE;ORAL | 018631-001 | Aug 30, 1984 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for TRENTAL
See the table below for patents covering TRENTAL around the world.
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
